文献速递中医内科中药与中成药合理使用

积雪草叶提取物与丙戊酸钠及苯妥英在大鼠癫痫模型中的药效与药代交互作用

Pharmacodynamic and pharmacokinetic interactions of hydroalcoholic leaf extract of Centella asiatica with valproate and phenytoin in experimental models of epilepsy in rats.
PubMed 文献 · J Ethnopharmacol · 2021-01-08

研究在大鼠戊四氮(PTZ)和最大电休克(MES)癫痫模型中评估积雪草水醇提取物(HECA)与丙戊酸钠(VPA)、苯妥英(PHT)联用的药效学与药代动力学交互作用。结果显示HECA与亚治疗剂量VPA或PHT联用可增强抗惊厥保护、减轻氧化应激和认知损害,并显著升高两药血清水平(p<0.001),同时改变药代参数,提示需密切临床监测以避免毒性反应。

要点

  • HECA与亚治疗剂量VPA或PHT联用可增强抗癫痫保护并减轻氧化应激与认知损害。
  • 联用可显著升高VPA和PHT血清水平并改变其药代参数,需警惕毒性反应。
  • 积雪草抑制CYP2C9、CYP2D6和CYP3A4,可能是 herb-drug 交互作用的机制基础。

核心结论

  • HECA与VPA或PHT联用可提高后两者抗癫痫疗效,但药代参数改变提示需严格医学监护以避免毒性反应。

研究设计与样本

  • 使用Wistar大鼠(175–200 g)进行药效学与药代动力学交互作用研究。
  • 药效学中分别以PTZ(60 mg/kg,腹腔注射)和MES(70 mA持续0.2 s)诱导癫痫。
  • VPA和PHT的治疗剂量与亚治疗剂量分别与HECA联用,评估行为学与脑氧化应激参数。
  • 药代动力学中采用HPLC测定不同时间点VPA和PHT血清水平,并用WinNonlin软件分析参数。

主要发现

  • VPA和PHT在治疗剂量下完全保护对抗癫痫发作,亚治疗剂量下无完全保护。
  • HECA与亚治疗剂量VPA或PHT联用增强癫痫保护,并显著(p<0.001)减轻癫痫诱导的氧化应激和认知损害。
  • 联用显著(p<0.001)升高VPA和PHT血清水平。
  • 联用后AEDs的最大血清浓度、曲线下面积和清除率等药代参数发生改变。

临床怎么用

  • 中医与中西医结合医生在癫痫患者联用积雪草与VPA或PHT时,应警惕血药浓度升高及毒性风险。
  • 建议在联用期间监测AEDs血清水平和临床毒性反应,必要时调整剂量。

局限性

  • 研究为大鼠实验模型,结论外推至人类临床需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Centella asiatica (CA) is commonly used herbal medicine for treatment of epilepsy. CA has CYP2C9, CYP2D6 and CYP3A4 enzymes inhibition property and used as an adjuvant therapy with conventional antiepileptic drugs (AEDs). That may be responsible for herb-drug interaction. AIM OF THE STUDY: The present study was planned to evaluate interactions profile of hydroalcoholic extract Centella asiatica (HECA) with antiepileptic drugs in experimental models of epilepsy in rats. MATERIALS AND METHODS: Wistar rats (175-200 g) were used. In the pharmacodynamic interaction study, seizures were induced using pentylenetetrazole (PTZ) (60 mg/kg, i.p.) and maximal electroshock seizure (MES) (70 mA for 0.2 s). The therapeutic and sub-therapeutic doses of valproate (VPA) and phenytoin (PHT) were co-administrated with HECA in PTZ and MES model of seizures respectively. Behavioural parameters were assessed using elevated plus maze test and passive avoidance paradigm. Rat brain oxidative stress parameters were also assessed. In the pharmacokinetic interaction study, the serum levels of the VPA and PHT were estimated at different time intervals by HPLC and pharmacokinetic parameters were analyzed by WinNonlin software. RESULTS: The VPA and PHT produced complete protection against seizures in their therapeutic doses but not with sub-therapeutic doses. However, co-administration of HECA with a sub-therapeutic dose of VPA and PHT enhanced the protection of seizures and significantly (p < 0.001) attenuated the seizure induced oxidative stress and cognitive impairment. It also significantly increased (p < 0.001) serum levels of VPA and PHT. The alterations in pharmacokinetic parameters (maximum serum concentration, area under the curve, clearance) of AEDs were also found with co-administration of HECA. CONCLUSION: The results suggested that co-administration of HECA could improve the therapeutic efficacy of VPA and PHT. But, alteration in pharmacokinetic parameters revel that needs critical medical supervision to avoid any toxic reactions.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Kumar R, Arora R, Sarangi SC, et al. Pharmacodynamic and pharmacokinetic interactions of hydroalcoholic leaf extract of Centella asiatica with valproate and phenytoin in experimental models of epilepsy in rats. J Ethnopharmacol. 2021. PMID: 33429032. doi:10.1016/j.jep.2021.113784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。